- ASSISTANT PROFESSOR | Neurology
- Hospital Affiliation
- The Mount Sinai Hospital
Neurology, American Board of Psychiatry and Neurology
- Botulinum Toxin Injections
- Electrodiagnostic Testing (EMG/NCS)
- Myasthenia Gravis
MD, University of Louisville
Internship, Internal Medicine
Maimonides Medical Center
Mount Sinai Hospital
Study of Eculizumab in Patients with GMG
The purpose of this study is to evaluate the safety of the drug eculizumab in a randomized, double-blind, placebo-controlled cross-over trial of patients with generalized Myasthenia Gravis (MG) who have not responded to other MG treatments.
Ochoa JL, Torebjork E, Marchettini P, Sivak M. Mechanisms of Neuropathic Pain: Cumulative Observations, New Experiments, and Further Speculation. In: Fields HL, Dubner R, Cervero F, editors. Advances in Pain Research and Therapy. New York, Raven; 1986. pp4-450.
Sivak M, Ochoa J. Clinical Electrophysiologic and Pathologic Correlates. In: Brown WF, Bolton CF, editors. Clinical Electromyography. Boston, CF Butterworths; 1987. pp3-30.
Sivak M, Ochoa J, Fernandez JM. Positive Manifestations of Nerve Fiber Dysfunction: Clinical Electrophysiologic and Pathologic Correlates. In: Brown WF, Bolton CF, editors. Clinical Electromyography. 2 Boston, Butterworth-Heimann; 1993. pp117-148.
Gluck M, Thomas RG, Sivak M. Unaltered cytochrome oxidase, glutamate dehydrogenase and glutaminase activities in platelets from patients with sporadic amyotrophic lateral sclerosis--a study of potential pathogenetic mechanisms in neurodegenerative diseases. J Neural Transm 2000; 107(12): 1437-47.
Begerman M, Sivak M. Concordance of Lupus Erythematosis and Myasthenia Gravis.;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Sivak did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.